Ultragenyx Pharmaceutical (RARE)Officer sold ~$41K

~$41K

Approx. value · 967 sh @ $42.10

50K

Holds after · shares reported

Traded

Mar 3, 2025

Filed

Mar 5, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Feb 27, 2025Insider · 1 personInsiders: 2 sales (~$128K)
2. Feb 28, 2025InsiderCEO sold ~$1.06M of RARE shares in the open market
3. Mar 3, 2025 · this disclosureInsiderOfficer sold ~$41K of RARE shares in the open market

What came next

1. Mar 3, 2025Insider · 6 peopleInsiders: 6 sales (~$5.5M)
2. Mar 6, 2025InsiderCFO sold ~$72K of RARE shares in the open market
3. Apr 21, 2025InsiderOfficer sold ~$8.5K of RARE shares in the open market
4. May 5, 2025InsiderOfficer sold ~$20K of RARE shares in the open market
5. Jun 20, 2025InsiderDirector sold ~$90K of RARE shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Ultragenyx Pharmaceutical

For Ultragenyx Pharmaceutical, OQRO holds 5 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its RARE page.

Other recent filings by Theodore Alan Huizenga, SVP, Chief Accounting Officer

• SEC Form 4 at Ultragenyx Pharmaceutical (RARE)Sep 19, 2025
• SEC Form 4 at Ultragenyx Pharmaceutical (RARE)Sep 8, 2025

The full history of Theodore Alan Huizenga, SVP, Chief Accounting Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Ultragenyx Pharmaceutical

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 13, 2026
• SEC Form 13F-HRMay 15, 2026

Everything OQRO holds on this company is on its RARE page.